NR 546 Psychopharmacology for the Psychiatric-
Mental Health Nurse Practitioner – Chamberlain
College of Nursing – Midterm Exam4 2026/2027
Question 1: A 34-year-old woman with major depressive disorder has been
prescribed an SSRI that selectively blocks the serotonin transporter. The
PMHNP understands that the therapeutic effect of SSRIs is mediated through
which downstream cellular mechanism?
A. Direct agonist activity at postsynaptic 5-HT2A receptors in the prefrontal cortex
B. Inhibition of monoamine oxidase type A in the presynaptic terminal
C. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased
serotonergic neurotransmission
D. Blockade of serotonin reuptake at the postsynaptic membrane
CORRECT ANSWER: C. Desensitization of presynaptic 5-HT1A autoreceptors
leading to increased serotonergic neurotransmission
Rationale: SSRIs block the serotonin transporter (SERT), acutely increasing synaptic
serotonin. However, this initial rise activates presynaptic 5-HT1A autoreceptors, which
inhibit serotonin release and cause the therapeutic lag. Over 2-4 weeks of chronic
treatment, these autoreceptors desensitize, disinhibiting serotonergic neurons and
enhancing neurotransmission to achieve therapeutic effects. Options A and B describe
mechanisms of other drug classes, while D is a reuptake blockade action not a
downstream mechanism .
Question 2: A 42-year-old man with schizophrenia is experiencing
gynecomastia and galactorrhea. His current antipsychotic is known to block
dopamine D2 receptors. Which pathway's blockade best explains this adverse
effect?
A. Mesolimbic pathway
B. Mesocortical pathway
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
CORRECT ANSWER: D. Tuberoinfundibular pathway
Rationale: The tuberoinfundibular pathway connects the hypothalamus to the anterior
pituitary. Dopamine released here acts as a Prolactin Inhibitory Factor (PIF), binding to
D2 receptors on lactotroph cells to suppress prolactin secretion. D2 receptor blockade
by antipsychotics in this pathway removes the inhibitory tone, causing
hyperprolactinemia and related symptoms (galactorrhea, gynecomastia). Options A, B,
and C are associated with therapeutic effects, negative symptoms, and EPS,
respectively .
Question 3: A 28-year-old patient with bipolar disorder is prescribed a
medication that blocks voltage-gated sodium channels and inhibits glutamate
release. This mechanism of action is most consistent with which medication?
,A. Lithium carbonate
B. Valproic acid
C. Carbamazepine
D. Lamotrigine
CORRECT ANSWER: C. Carbamazepine
Rationale: Carbamazepine, an anticonvulsant mood stabilizer, works primarily by
blocking voltage-gated sodium channels, which inhibits the release of glutamate and
other excitatory neurotransmitters. This action stabilizes neuronal membranes and is
effective for acute mania and maintenance in bipolar disorder. Valproic acid and
lamotrigine have similar but distinct mechanisms, and lithium's primary mechanism
involves second messenger systems .
Question 4: Which statement accurately describes the role of the enzyme
catechol-O-methyltransferase (COMT) in the synaptic cleft?
A. It synthesizes dopamine from tyrosine.
B. It is responsible for the reuptake of serotonin into the presynaptic neuron.
C. It degrades catecholamines (dopamine, norepinephrine) in the synapse and
extracellular space.
D. It converts norepinephrine into epinephrine in the adrenal medulla.
CORRECT ANSWER: C. It degrades catecholamines (dopamine,
norepinephrine) in the synapse and extracellular space.
Rationale: COMT is a key metabolic enzyme that breaks down catecholamines like
dopamine and norepinephrine in the synapse and extracellular space. While MAO acts
intracellularly, COMT acts extracellularly, playing a critical role in terminating the action
of these neurotransmitters. Option A describes the synthesis pathway, B describes a
transporter, and D describes a process in the adrenal medulla .
Question 5: A PMHNP is reviewing a patient's genetic test results showing a
CYP2D6 "poor metabolizer" phenotype. When prescribing a medication that is
a CYP2D6 substrate, what should the PMHNP anticipate?
A. Faster drug clearance, requiring higher doses.
B. Increased risk of adverse effects at standard doses.
C. No significant change in drug metabolism.
D. Complete inactivation of the medication.
CORRECT ANSWER: B. Increased risk of adverse effects at standard doses.
Rationale: Poor metabolizers have significantly reduced or absent CYP2D6 enzyme
activity. This leads to higher-than-expected plasma concentrations of drugs that rely on
this pathway for clearance, increasing the risk for dose-dependent adverse effects. The
PMHNP should consider starting at a lower dose or choosing a different medication .
Question 6: A patient's depression is believed to be related to alterations in
intracellular signaling. Which medication class directly inhibits the reuptake of
,both serotonin and norepinephrine without directly acting on intracellular
machinery?
A. MAOI
B. SSRI
C. SNRI
D. Tricyclic Antidepressant (TCA)
CORRECT ANSWER: C. SNRI
Rationale: SNRIs (e.g., venlafaxine, duloxetine) block the reuptake pumps
(transporters) for both serotonin and norepinephrine, increasing their availability in the
synaptic cleft. This action directly impacts monoamine levels, though it indirectly
triggers intracellular changes. In contrast, MAOIs act on an intracellular enzyme, SSRIs
are selective for serotonin, and TCAs, while inhibiting both, have a broader receptor
profile .
Question 7: Which brain region is primarily responsible for executive function,
decision-making, and is implicated in the negative symptoms of
schizophrenia?
A. Amygdala
B. Hippocampus
C. Prefrontal cortex
D. Nucleus accumbens
CORRECT ANSWER: C. Prefrontal cortex
Rationale: The prefrontal cortex (PFC) governs executive functions, working memory,
and impulse control. Hypofunction of the mesocortical dopamine pathway (VTA to PFC)
is strongly linked to the negative symptoms of schizophrenia (avolition, alogia, flat
affect). The amygdala processes fear, the hippocampus is involved in memory, and the
nucleus accumbens is the core reward center .
Question 8: The PMHNP is explaining the "chemical imbalance" theory to a
patient with major depressive disorder. Which statement best reflects the
modern neurobiological understanding of depression?
A. Depression is solely caused by low serotonin levels.
B. Depression is a genetic disorder with no environmental influence.
C. Depression is associated with altered neuroplasticity, monoamine dysregulation, and
disrupted functional connectivity.
D. Depression is best treated by correcting a deficiency in dopamine.
CORRECT ANSWER: C. Depression is associated with altered neuroplasticity,
monoamine dysregulation, and disrupted functional connectivity.
Rationale: The modern neurobiological view of depression has evolved beyond a
simple "chemical imbalance." It now encompasses a complex interplay of factors
including monoamine dysregulation, impaired neuroplasticity (often linked to decreased
, BDNF), and altered functional connectivity across various brain networks. This holistic
view explains the delayed therapeutic effect of antidepressants, which work by
promoting neuroplasticity over time .
Question 9: Which statement best describes the function of a second
messenger in neuronal signaling?
A. It directly opens the chloride channel on the GABA-A receptor.
B. It transports neurotransmitters back into the presynaptic neuron.
C. It amplifies the intracellular signal initiated by a neurotransmitter binding to a
receptor.
D. It degrades monoamines in the synaptic cleft.
CORRECT ANSWER: C. It amplifies the intracellular signal initiated by a
neurotransmitter binding to a receptor.
Rationale: Second messengers (e.g., cyclic AMP, IP3) are molecules that relay and
amplify signals received by cell surface receptors. When a first messenger
(neurotransmitter) binds to a G-protein coupled receptor, it can trigger the production of
second messengers, which then set off a cascade of intracellular events, leading to a
larger cellular response. This is a key mechanism for signal transduction .
Question 10: The myelin sheath surrounding axons in the central nervous
system is produced by which cell type?
A. Schwann cells
B. Oligodendrocytes
C. Astrocytes
D. Microglia
CORRECT ANSWER: B. Oligodendrocytes
Rationale: Oligodendrocytes are the myelinating cells of the central nervous system
(CNS). Schwann cells provide myelin in the peripheral nervous system (PNS). Astrocytes
provide metabolic support and form the blood-brain barrier, while microglia act as the
CNS's immune cells. This distinction is clinically relevant, as demyelinating diseases like
multiple sclerosis affect oligodendrocytes .
Question 11: A patient is prescribed a medication that acts as a full agonist at
the serotonin 1A (5-HT1A) receptor. Which downstream effect would the
PMHNP expect?
A. Increased dopamine release in the mesolimbic pathway
B. Decreased anxiety and blunted stress response
C. Significant prolongation of the QT interval
D. Increased histamine release leading to sedation
CORRECT ANSWER: B. Decreased anxiety and blunted stress response
Mental Health Nurse Practitioner – Chamberlain
College of Nursing – Midterm Exam4 2026/2027
Question 1: A 34-year-old woman with major depressive disorder has been
prescribed an SSRI that selectively blocks the serotonin transporter. The
PMHNP understands that the therapeutic effect of SSRIs is mediated through
which downstream cellular mechanism?
A. Direct agonist activity at postsynaptic 5-HT2A receptors in the prefrontal cortex
B. Inhibition of monoamine oxidase type A in the presynaptic terminal
C. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased
serotonergic neurotransmission
D. Blockade of serotonin reuptake at the postsynaptic membrane
CORRECT ANSWER: C. Desensitization of presynaptic 5-HT1A autoreceptors
leading to increased serotonergic neurotransmission
Rationale: SSRIs block the serotonin transporter (SERT), acutely increasing synaptic
serotonin. However, this initial rise activates presynaptic 5-HT1A autoreceptors, which
inhibit serotonin release and cause the therapeutic lag. Over 2-4 weeks of chronic
treatment, these autoreceptors desensitize, disinhibiting serotonergic neurons and
enhancing neurotransmission to achieve therapeutic effects. Options A and B describe
mechanisms of other drug classes, while D is a reuptake blockade action not a
downstream mechanism .
Question 2: A 42-year-old man with schizophrenia is experiencing
gynecomastia and galactorrhea. His current antipsychotic is known to block
dopamine D2 receptors. Which pathway's blockade best explains this adverse
effect?
A. Mesolimbic pathway
B. Mesocortical pathway
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
CORRECT ANSWER: D. Tuberoinfundibular pathway
Rationale: The tuberoinfundibular pathway connects the hypothalamus to the anterior
pituitary. Dopamine released here acts as a Prolactin Inhibitory Factor (PIF), binding to
D2 receptors on lactotroph cells to suppress prolactin secretion. D2 receptor blockade
by antipsychotics in this pathway removes the inhibitory tone, causing
hyperprolactinemia and related symptoms (galactorrhea, gynecomastia). Options A, B,
and C are associated with therapeutic effects, negative symptoms, and EPS,
respectively .
Question 3: A 28-year-old patient with bipolar disorder is prescribed a
medication that blocks voltage-gated sodium channels and inhibits glutamate
release. This mechanism of action is most consistent with which medication?
,A. Lithium carbonate
B. Valproic acid
C. Carbamazepine
D. Lamotrigine
CORRECT ANSWER: C. Carbamazepine
Rationale: Carbamazepine, an anticonvulsant mood stabilizer, works primarily by
blocking voltage-gated sodium channels, which inhibits the release of glutamate and
other excitatory neurotransmitters. This action stabilizes neuronal membranes and is
effective for acute mania and maintenance in bipolar disorder. Valproic acid and
lamotrigine have similar but distinct mechanisms, and lithium's primary mechanism
involves second messenger systems .
Question 4: Which statement accurately describes the role of the enzyme
catechol-O-methyltransferase (COMT) in the synaptic cleft?
A. It synthesizes dopamine from tyrosine.
B. It is responsible for the reuptake of serotonin into the presynaptic neuron.
C. It degrades catecholamines (dopamine, norepinephrine) in the synapse and
extracellular space.
D. It converts norepinephrine into epinephrine in the adrenal medulla.
CORRECT ANSWER: C. It degrades catecholamines (dopamine,
norepinephrine) in the synapse and extracellular space.
Rationale: COMT is a key metabolic enzyme that breaks down catecholamines like
dopamine and norepinephrine in the synapse and extracellular space. While MAO acts
intracellularly, COMT acts extracellularly, playing a critical role in terminating the action
of these neurotransmitters. Option A describes the synthesis pathway, B describes a
transporter, and D describes a process in the adrenal medulla .
Question 5: A PMHNP is reviewing a patient's genetic test results showing a
CYP2D6 "poor metabolizer" phenotype. When prescribing a medication that is
a CYP2D6 substrate, what should the PMHNP anticipate?
A. Faster drug clearance, requiring higher doses.
B. Increased risk of adverse effects at standard doses.
C. No significant change in drug metabolism.
D. Complete inactivation of the medication.
CORRECT ANSWER: B. Increased risk of adverse effects at standard doses.
Rationale: Poor metabolizers have significantly reduced or absent CYP2D6 enzyme
activity. This leads to higher-than-expected plasma concentrations of drugs that rely on
this pathway for clearance, increasing the risk for dose-dependent adverse effects. The
PMHNP should consider starting at a lower dose or choosing a different medication .
Question 6: A patient's depression is believed to be related to alterations in
intracellular signaling. Which medication class directly inhibits the reuptake of
,both serotonin and norepinephrine without directly acting on intracellular
machinery?
A. MAOI
B. SSRI
C. SNRI
D. Tricyclic Antidepressant (TCA)
CORRECT ANSWER: C. SNRI
Rationale: SNRIs (e.g., venlafaxine, duloxetine) block the reuptake pumps
(transporters) for both serotonin and norepinephrine, increasing their availability in the
synaptic cleft. This action directly impacts monoamine levels, though it indirectly
triggers intracellular changes. In contrast, MAOIs act on an intracellular enzyme, SSRIs
are selective for serotonin, and TCAs, while inhibiting both, have a broader receptor
profile .
Question 7: Which brain region is primarily responsible for executive function,
decision-making, and is implicated in the negative symptoms of
schizophrenia?
A. Amygdala
B. Hippocampus
C. Prefrontal cortex
D. Nucleus accumbens
CORRECT ANSWER: C. Prefrontal cortex
Rationale: The prefrontal cortex (PFC) governs executive functions, working memory,
and impulse control. Hypofunction of the mesocortical dopamine pathway (VTA to PFC)
is strongly linked to the negative symptoms of schizophrenia (avolition, alogia, flat
affect). The amygdala processes fear, the hippocampus is involved in memory, and the
nucleus accumbens is the core reward center .
Question 8: The PMHNP is explaining the "chemical imbalance" theory to a
patient with major depressive disorder. Which statement best reflects the
modern neurobiological understanding of depression?
A. Depression is solely caused by low serotonin levels.
B. Depression is a genetic disorder with no environmental influence.
C. Depression is associated with altered neuroplasticity, monoamine dysregulation, and
disrupted functional connectivity.
D. Depression is best treated by correcting a deficiency in dopamine.
CORRECT ANSWER: C. Depression is associated with altered neuroplasticity,
monoamine dysregulation, and disrupted functional connectivity.
Rationale: The modern neurobiological view of depression has evolved beyond a
simple "chemical imbalance." It now encompasses a complex interplay of factors
including monoamine dysregulation, impaired neuroplasticity (often linked to decreased
, BDNF), and altered functional connectivity across various brain networks. This holistic
view explains the delayed therapeutic effect of antidepressants, which work by
promoting neuroplasticity over time .
Question 9: Which statement best describes the function of a second
messenger in neuronal signaling?
A. It directly opens the chloride channel on the GABA-A receptor.
B. It transports neurotransmitters back into the presynaptic neuron.
C. It amplifies the intracellular signal initiated by a neurotransmitter binding to a
receptor.
D. It degrades monoamines in the synaptic cleft.
CORRECT ANSWER: C. It amplifies the intracellular signal initiated by a
neurotransmitter binding to a receptor.
Rationale: Second messengers (e.g., cyclic AMP, IP3) are molecules that relay and
amplify signals received by cell surface receptors. When a first messenger
(neurotransmitter) binds to a G-protein coupled receptor, it can trigger the production of
second messengers, which then set off a cascade of intracellular events, leading to a
larger cellular response. This is a key mechanism for signal transduction .
Question 10: The myelin sheath surrounding axons in the central nervous
system is produced by which cell type?
A. Schwann cells
B. Oligodendrocytes
C. Astrocytes
D. Microglia
CORRECT ANSWER: B. Oligodendrocytes
Rationale: Oligodendrocytes are the myelinating cells of the central nervous system
(CNS). Schwann cells provide myelin in the peripheral nervous system (PNS). Astrocytes
provide metabolic support and form the blood-brain barrier, while microglia act as the
CNS's immune cells. This distinction is clinically relevant, as demyelinating diseases like
multiple sclerosis affect oligodendrocytes .
Question 11: A patient is prescribed a medication that acts as a full agonist at
the serotonin 1A (5-HT1A) receptor. Which downstream effect would the
PMHNP expect?
A. Increased dopamine release in the mesolimbic pathway
B. Decreased anxiety and blunted stress response
C. Significant prolongation of the QT interval
D. Increased histamine release leading to sedation
CORRECT ANSWER: B. Decreased anxiety and blunted stress response
